| ISSN |
1948-0210 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Surgery |
| Manuscript Type |
Clinical Trials Study |
| Article Title |
Multiroute administration of Wharton’s jelly mesenchymal stem cells in chronic complete spinal cord injury: A phase I safety and feasibility study
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Necati Kaplan, Serdar Kabatas, Erdinç Civelek, Eyüp Can Savrunlu, Tolga Akkoc, Osman Boyalı, Erek Öztürk, Halil Can, Ali Genc and Erdal Karaöz |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Serdar Kabatas, Full Professor, MD, Department of Neurosurgery, University of Health Sciences Turkey, Gaziosmanpaşa Training and Research Hospital, Karayolları Mahallesi, Osmanbey Caddesi 616. Sokak No. 10, Gaziosmanpaşa, Istanbul 34255, Türkiye. kabatasserdar@hotmail.com |
| Key Words |
Spinal cord injury; Mesenchymal stem cell; Transplantation; Wharton’s jelly; Neurological recovery |
| Core Tip |
Spinal cord injury causes severe disability, leading to significant impairments in sensory and motor functions, as well as dysfunction in multiple organs, greatly diminishing the quality of life. This study investigated the therapeutic potential of Wharton’s jelly-derived mesenchymal stem cells administered through a triple-route delivery system (intrathecal, intramuscular, and intravenous) over multiple sessions. The treatment resulted in significant improvements in both motor and sensory functions, with a noticeable reduction in spasticity. Additionally, patients experienced an improved quality of life, particularly with enhancements in urinary and bowel incontinence. The procedure was well-tolerated by all participants, with no significant side effects or safety concerns. Importantly, no adverse events were reported during the one-year follow-up period, highlighting the potential of Wharton's jelly-derived mesenchymal stem cells therapy as a safe and effective treatment option for individuals with chronic spinal cord injury. |
| Publish Date |
2025-05-26 09:15 |
| Citation |
Kaplan N, Kabatas S, Civelek E, Savrunlu EC, Akkoc T, Boyalı O, Öztürk E, Can H, Genc A, Karaöz E. Multiroute administration of Wharton’s jelly mesenchymal stem cells in chronic complete spinal cord injury: A phase I safety and feasibility study. World J Stem Cells 2025; 17(5): 101675 |
| URL |
https://www.wjgnet.com/1948-0210/full/v17/i5/101675.htm |
| DOI |
https://dx.doi.org/10.4252/wjsc.v17.i5.101675 |
